Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks

10:20 EDT 25 Apr 2019 | Proactive Investors

The mid-stage study is testing Scancell’s flagship skin cancer immunotherapy in combination with Keytruda – the blockbuster checkpoint inhibitor developed by Merck

More From BioPortfolio on "Scancell higher as it is to begin UK arm of phase II skin cancer trial within weeks"